MicroRNA‑873 inhibits the progression of thyroid cancer by directly targeting ZEB1

Jiao,Dan; Guo,Feng; Fu,Qingfeng

doi:10.3892/mmr.2019.10381

MicroRNA‑873 inhibits the progression of thyroid cancer by directly targeting ZEB1

Authors:
- Dan Jiao
- Feng Guo
- Qingfeng Fu
View Affiliations

Affiliations: Department of Ultrasound, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Division of Thyroid Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: June 12, 2019 https://doi.org/10.3892/mmr.2019.10381
Pages: 1986-1993

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent evidence has revealed that certain microRNAs (miRNAs) are dysregulated in thyroid cancer (TC), which has been associated with the pathogenesis and development of TC. Therefore, improved understanding of the detailed roles of miRNAs that are aberrantly expressed in TC may aid the development of valuable therapeutic methods for the management of patients with this malignancy. In this study, miRNA‑873‑5p (miR‑873) expression in TC tissues and cell lines was detected by reverse‑transcription quantitative polymerase chain reaction (RT‑qPCR). MTT and cell invasion assays were performed to investigate the effects of miR‑873 overexpression on TC cell proliferation and invasion in vitro. Bioinformatics analysis, luciferase reporter assay, RT‑qPCR and western blot analysis were employed to evaluate whether zinc finger E‑box‑binding homeobox 1 (ZEB1) is a direct target of miR‑873 in TC cells. The present study reported that miR‑873 was weakly expressed in human TC tissues and cell lines. Functionally, miR‑873 overexpression suppressed TC cell proliferation and invasion in vitro. Mechanistically, ZEB1 was predicted to be a putative target of miR‑873. In addition, miR‑873 was proposed to directly bind to the 3'‑untranslated region of ZEB1 and decrease its expression in TC cells at the mRNA and protein levels. Furthermore, ZEB1 expression was significantly upregulated in TC tissues and negatively correlated with miR‑873 expression. Furthermore, ZEB1 restoration partially reversed the suppressive effects of miR‑873 overexpression on TC cell proliferation and invasion. These results demonstrated that miR‑873 may serve tumour‑suppressive roles in the progression of TC, and its suppressive effects could be mediated by the inhibition of ZEB1. Therefore, miR‑873 may be a valuable therapeutic target in the management of patients with TC.

View Figures

View References

1	Liebner DA and Shah MH: Thyroid cancer: Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
2	Lloyd RV, Buehler D and Khanafshar E: Papillary thyroid carcinoma variants. Head Neck Pathol. 5:51–56. 2011. View Article : Google Scholar : PubMed/NCBI
3	Das S, Chaudhary N, Ang LC and Megyesi JS: Papillary thyroid carcinoma metastasizing to anaplastic meningioma: An unusual case of tumor-to-tumor metastasis. Brain Tumor Pathol. 34:130–134. 2017. View Article : Google Scholar : PubMed/NCBI
4	Nikiforov YE and Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
5	Liu S, Semenciw R, Ugnat AM and Mao Y: Increasing thyroid cancer incidence in Canada, 1970–1996: Time trends and age-period-cohort effects. Br J Cancer. 85:1335–1339. 2001. View Article : Google Scholar : PubMed/NCBI
6	Pemayun TG: Current diagnosis and management of thyroid nodules. Acta Med Indones. 48:247–257. 2016.PubMed/NCBI
7	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
8	Jia L, Zhang D, Qi X, Ma B, Xiang Z and He N: Identification of the conserved and novel miRNAs in Mulberry by high-throughput sequencing. PLoS One. 9:e1044092014. View Article : Google Scholar : PubMed/NCBI
9	Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mutalib NS, Yusof AM, Mokhtar NM, Harun R, Muhammad R and Jamal R: MicroRNAs and lymph node metastasis in papillary thyroid cancers. Asian Pac J Cancer Prev. 17:25–35. 2016. View Article : Google Scholar : PubMed/NCBI
11	Xu J, Li J, Zheng TH, Bai L and Liu ZJ: MicroRNAs in the occurrence and development of primary hepatocellular carcinoma. Adv Clin Exp Med. 25:971–975. 2016. View Article : Google Scholar : PubMed/NCBI
12	Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
13	Irmak-Yazicioglu MB: Mechanisms of MicroRNA deregulation and MicroRNA targets in gastric cancer. Oncol Res Treat. 39:136–139. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhang M, Wu W, Gao M and Fei Z: MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma. Cancer Biomark. 19:437–445. 2017. View Article : Google Scholar : PubMed/NCBI
15	Liu J, Li Q, Li R, Ren P and Dong S: MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA. Am J Cancer Res. 7:148–158. 2017.PubMed/NCBI
16	Zhao H, Tang H, Huang Q, Qiu B, Liu X, Fan D, Gong L, Guo H, Chen C, Lei S, et al: MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma. Am J Cancer Res. 6:2575–2586. 2016.PubMed/NCBI
17	Gong H, Fang L, Li Y, Du J, Zhou B, Wang X, Zhou H, Gao L, Wang K and Zhang J: miR873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1. Oncol Rep. 39:1090–1098. 2018.PubMed/NCBI
18	Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene. 34:40182015. View Article : Google Scholar : PubMed/NCBI
19	Cao D, Yu T and Ou X: MiR-873-5P controls gastric cancer progression by targeting hedgehog-GLI signaling. Pharmazie. 71:603–606. 2016.PubMed/NCBI
20	Chen XY, Chen RP, Wu W and Huang ZM: MicroRNA-873 inhibits proliferation and induces apoptosis by targeting CXCL1 in gastric cancer. Int J Clin Exp Pathol. 9:10011–10019. 2016.
21	Liu ZY, Zhou GY, Kakudo K and Lam AK: Update on 2017 Who classification of tumors of thyroid gland. Zhonghua Bing Li Xue Za Zhi. 47:302–306. 2018.(In Chinese). PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y, Liu G, Wu S, Jiang F, Xie J and Wang Y: Zinc finger E-box-binding homeobox 1: Its clinical significance and functional role in human thyroid cancer. Onco Targets Ther. 9:1303–1310. 2016.PubMed/NCBI
24	Wang Z, Zhang H, He L, Dong W, Li J, Shan Z and Teng W: Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther. 6:281–287. 2013. View Article : Google Scholar : PubMed/NCBI
25	Graham ME, Hart RD, Douglas S, Makki FM, Pinto D, Butler AL, Bullock M, Rigby MH, Trites JR, Taylor SM and Singh R: Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses. J Otolaryngol Head Neck Surg. 44:332015. View Article : Google Scholar : PubMed/NCBI
26	Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG and Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 119:4358–4365. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wu DD, Li XS, Meng XN, Yan J and Zong ZH: MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
29	Gao Y, Xue Q, Wang D, Du M, Zhang Y and Gao S: miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1. Am J Transl Res. 7:2519–2526. 2015.PubMed/NCBI
30	Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhang Y, Xu L, Li A and Han X: The roles of ZEB1 in tumorigenic progression and epigenetic modifications. Biomed Pharmacother. 110:400–408. 2019. View Article : Google Scholar : PubMed/NCBI
32	Ma Y, Zheng X, Zhou J, Zhang Y and Chen K: ZEB1 promotes the progression and metastasis of cervical squamous cell carcinoma via the promotion of epithelial-mesenchymal transition. Int J Clin Exp Pathol. 8:11258–11267. 2015.PubMed/NCBI
33	Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et al: ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
34	Zhou YM, Cao L, Li B, Zhang RX, Sui CJ, Yin ZF and Yang JM: Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol. 19:1700–1706. 2012. View Article : Google Scholar : PubMed/NCBI
35	Jia B, Liu H, Kong Q and Li B: Overexpression of ZEB1 associated with metastasis and invasion in patients with gastric carcinoma. Mol Cell Biochem. 366:223–229. 2012. View Article : Google Scholar : PubMed/NCBI
36	Guo E, Wang Z and Wang S: MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration. Eur Rev Med Pharmacol Sci. 20:3385–3391. 2016.PubMed/NCBI